Literature DB >> 21160962

Proteinases and their inhibitors in liver cancer.

Verena Puxbaum1, Lukas Mach.   

Abstract

Proteinases are known to be involved in many cancer-related processes, particularly in the breakdown of extracellular matrix barriers in the course of tumor invasion and metastasis. In this review we summarize the current knowledge about the role of the most important matrix-degrading proteinases (cathepsins, matrix metalloproteinases, plasmin/plasminogen activators) and their respective inhibitors in liver cancer progression and metastasis.

Entities:  

Keywords:  Cathepsin; Cystatin; Hepatocellular carcinoma; Metalloproteinase; Metastasis; Plasminogen activator; Tumor invasion

Year:  2009        PMID： 21160962      PMCID： PMC2998952          DOI： 10.4254/wjh.v1.i1.28

Source DB:  PubMed          Journal:  World J Hepatol


  88 in total

1.  Physiological mechanisms for metalloproteinase activation.

Authors:  G Murphy; R Ward; J Gavrilovic; S Atkinson
Journal:  Matrix Suppl       Date:  1992

Review 2.  The cystatins: protein inhibitors of cysteine proteinases.

Authors:  V Turk; W Bode
Journal:  FEBS Lett       Date:  1991-07-22       Impact factor: 4.124

3.  CMAP: a novel cystatin-like gene involved in liver metastasis.

Authors:  M Morita; N Yoshiuchi; H Arakawa; S Nishimura
Journal:  Cancer Res       Date:  1999-01-01       Impact factor: 12.701

4.  Modulation of cystatin C expression impairs the invasive and tumorigenic potential of human glioblastoma cells.

Authors:  Santhi D Konduri; Niranjan Yanamandra; Khawar Siddique; Arun Joseph; Dzung H Dinh; William C Olivero; Meena Gujrati; Gregory Kouraklis; Amand Swaroop; Athanassios P Kyritsis; Jasti S Rao
Journal:  Oncogene       Date:  2002-12-12       Impact factor: 9.867

5.  Maturation of human procathepsin B. Proenzyme activation and proteolytic processing of the precursor to the mature proteinase, in vitro, are primarily unimolecular processes.

Authors:  L Mach; J S Mort; J Glössl
Journal:  J Biol Chem       Date:  1994-04-29       Impact factor: 5.157

6.  Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L.

Authors:  L Goretzki; M Schmitt; K Mann; J Calvete; N Chucholowski; M Kramer; W A Günzler; F Jänicke; H Graeff
Journal:  FEBS Lett       Date:  1992-02-03       Impact factor: 4.124

Review 7.  The plasminogen activation system in tumor growth, invasion, and metastasis.

Authors:  P A Andreasen; R Egelund; H H Petersen
Journal:  Cell Mol Life Sci       Date:  2000-01-20       Impact factor: 9.261

8.  Transgenic TIMP-1 inhibits simian virus 40 T antigen-induced hepatocarcinogenesis by impairment of hepatocellular proliferation and tumor angiogenesis.

Authors:  D C Martin; O H Sanchez-Sweatman; A T Ho; D S Inderdeo; M S Tsao; R Khokha
Journal:  Lab Invest       Date:  1999-02       Impact factor: 5.662

9.  The lysosomal trafficking of sphingolipid activator proteins (SAPs) is mediated by sortilin.

Authors:  Stephane Lefrancois; Jibin Zeng; A Jacob Hassan; Maryssa Canuel; Carlos R Morales
Journal:  EMBO J       Date:  2003-12-15       Impact factor: 11.598

10.  Noncovalent complexes between the lysosomal proteinase cathepsin B and its propeptide account for stable, extracellular, high molecular mass forms of the enzyme.

Authors:  L Mach; J S Mort; J Glössl
Journal:  J Biol Chem       Date:  1994-04-29       Impact factor: 5.157
View more
  5 in total

1.  M6P/IGF2R modulates the invasiveness of liver cells via its capacity to bind mannose 6-phosphate residues.

Authors:  Verena Puxbaum; Elisabeth Nimmerfall; Christine Bäuerl; Nicole Taub; Pia-Maria Blaas; Johannes Wieser; Mario Mikula; Wolfgang Mikulits; Ken M Ng; George C T Yeoh; Lukas Mach
Journal:  J Hepatol       Date:  2012-04-17       Impact factor: 25.083

2.  How echinoccocosis affects potential cancer markers in plasma: galectin-3, sN-cadherin and sE-cadherin? A preliminary report.

Authors:  Joanna Giebultowicz; Malgorzata Polanska-Plachta; Piotr Wroczynski; Piotr Zaborowski; Jerzy A Polanski
Journal:  Diagn Pathol       Date:  2012-02-18       Impact factor: 2.644

3.  Cystatin F acts as a mediator of immune suppression in glioblastoma.

Authors:  Emanuela Senjor; Milica Perišić Nanut; Barbara Breznik; Ana Mitrović; Jernej Mlakar; Ana Rotter; Andrej Porčnik; Tamara Lah Turnšek; Janko Kos
Journal:  Cell Oncol (Dordr)       Date:  2021-06-29       Impact factor: 6.730

4.  Baicalein inhibits the invasion and metastatic capabilities of hepatocellular carcinoma cells via down-regulation of the ERK pathway.

Authors:  Kunlun Chen; Shu Zhang; Yuanyuan Ji; Jun Li; Peng An; Hongtao Ren; Rongrui Liang; Jun Yang; Zongfang Li
Journal:  PLoS One       Date:  2013-09-06       Impact factor: 3.240

Review 5.  Lysosomal peptidases-intriguing roles in cancer progression and neurodegeneration.

Authors:  Janko Kos; Ana Mitrović; Milica Perišić Nanut; Anja Pišlar
Journal:  FEBS Open Bio       Date:  2022-02-03       Impact factor: 2.693
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.